STE.NYSESteris PLC

Form 4: STERIS VP & Treasurer Exercises Options, Sells Shares

Sentiment:

Insider Transaction Report


STERIS plc's VP & Corporate Treasurer, Renato Tamaro, exercised stock options and subsequently sold the acquired shares on August 20, 2025.

Summary

  • Renato Tamaro, VP & Corporate Treasurer of STERIS plc, engaged in a stock transaction on August 20, 2025.
  • Exercised an employee stock option to acquire 3,204 ordinary shares at an exercise price of $147.05 per share.
  • Immediately after, sold all 3,204 acquired ordinary shares at a weighted average price of $249.24 per share.
  • The sale price for the disposed shares ranged from $249.145 to $249.34 per share.
  • Following these transactions, Tamaro beneficially owns 7,221 ordinary shares of STERIS plc.
  • 1,561 of the remaining ordinary shares are restricted, with vesting schedules extending to June 5, 2028.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. While an insider sale can sometimes be viewed negatively, this appears to be a routine exercise-and-sell transaction for equity compensation, indicating the executive is realizing value from vested options. The significant profit margin between exercise and sale price is positive for the executive.

Positives

  • The executive realized a significant profit from exercising options and selling shares, indicating a personal financial gain.
  • The sale price of $249.24 per share is substantially higher than the exercise price of $147.05, reflecting a strong stock performance for the period the options were held.

Negatives

  • An insider sale, even if for option exercise and tax purposes, can sometimes be perceived negatively by the market as it reduces the executive's direct equity stake.

Future Outlook

The filing does not provide specific forward-looking statements or guidance, focusing solely on past insider transactions.

Industry Context

This Form 4 reports a routine insider transaction (exercise and sell-to-cover) for an executive at STERIS plc, a company operating in the healthcare and life sciences industry. Such transactions are common for executives managing their equity compensation and do not inherently indicate broader industry trends or competitive shifts.

Comparison to Industry Standards

  • This Form 4 details an insider transaction, which is a standard practice for executives managing their equity compensation. It does not provide financial results or operational metrics that can be directly compared to industry benchmarks or specific competitors like Getinge, Cantel Medical (now part of STERIS), or Ecolab's healthcare division.
  • The transaction itself is a common mechanism for executives to realize value from vested stock options, often to cover taxes or for personal financial planning.

Stakeholder Impact

  • Shareholders: The transaction represents a minor reduction in direct insider ownership, which is common for equity compensation management. The executive still retains a significant number of shares, including restricted ones.
  • Employees: No direct impact on employees is indicated by this filing.

Next Steps

  • Future lapse dates for restricted ordinary shares held by the reporting person: 86 shares on October 1, 2025; 241 shares on June 1, 2026; 141 shares on June 2, 2026; 217 shares on June 3, 2026; 221 shares on June 4, 2026; 217 shares on June 3, 2027; 221 shares on June 4, 2027; and 217 shares on June 5, 2028.

Key Dates

DateDescription
05/31/2019Employee stock option for 3,204 shares awarded.
08/20/2025Date of stock option exercise and subsequent sale of shares.
08/21/2025Date as of which 1,561 ordinary shares are restricted.
10/01/2025Restriction lapses on 86 ordinary shares.
06/01/2026Restriction lapses on 241 ordinary shares.
06/02/2026Restriction lapses on 141 ordinary shares.
06/03/2026Restriction lapses on 217 ordinary shares.
06/04/2026Restriction lapses on 221 ordinary shares.
06/03/2027Restriction lapses on 217 ordinary shares.
06/04/2027Restriction lapses on 221 ordinary shares.
06/05/2028Restriction lapses on 217 ordinary shares.
05/31/2029Expiration date of the exercised employee stock option.
08/22/2025Signature date of the filing.

Recommendation

hold

This Form 4 details a routine insider transaction where an executive exercised vested stock options and sold the acquired shares. Such transactions are common for managing equity compensation and do not typically signal a change in the company's fundamental outlook or performance. The executive retains a substantial number of shares, including restricted ones, indicating continued alignment with shareholder interests. Therefore, based solely on this filing, a 'hold' recommendation is appropriate as it provides no new information to alter the investment thesis for STERIS plc.

Keywords

STERIS plc, STE, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Renato Tamaro, Corporate Treasurer, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.